Malignant hypertension and interferon-beta: a case report.
Renal Unit, Hôpital de la Côte Basque, Bayonne, France.
S
S
Rubin
Renal Unit, Hôpital de la Côte Basque, Bayonne, France.
A
A
Lacraz
Renal Unit, Hôpital de la Côte Basque, Bayonne, France.
V
V
Galantine
Cardiology and Hypertension, Hopital Saint André, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.
P
P
Gosse
D000328:Adult; D000959:Antihypertensive Agents / Q000008:administration & dosage; D001262:Atenolol / Q000008:administration & dosage; D001713:Biphenyl Compounds / Q000008:administration & dosage; D017298:Bisoprolol / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D006974:Hypertension, Malignant / Q000139:chemically induced* / Q000188:drug therapy* / Q000503:physiopathology; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects; D016899:Interferon-beta / Q000008:administration & dosage / Q000009:adverse effects*; D000077405:Irbesartan; D009103:Multiple Sclerosis / Q000188:drug therapy*; D017257:Ramipril / Q000008:administration & dosage; D012084:Renin-Angiotensin System / Q000187:drug effects; D013777:Tetrazoles / Q000008:administration & dosage
D000959:Antihypertensive Agents; D001713:Biphenyl Compounds; D007155:Immunologic Factors; D013777:Tetrazoles; D001262:Atenolol; D016899:Interferon-beta; D000077405:Irbesartan; D017257:Ramipril; D017298:Bisoprolol